CERS2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Fingolimod (SCHEMBL7445)	1.00	1/20
SCHEMBL1372656	1.00	1/20
SCHEMBL3389578	1.00	1/20
SCHEMBL3390328	1.00	1/20
SCHEMBL3391728	1.00	1/20
SCHEMBL3392313	1.00	1/20
SCHEMBL3393539	1.00	1/20
SCHEMBL3394554	1.00	1/20
SCHEMBL3394797	1.00	1/20
Fingolimod (SCHEMBL81362)	0.97	1/20
Fingolimod (SCHEMBL947820)	0.94	1/20
SCHEMBL1313426	0.88	1/20
SCHEMBL1286791	0.82	1/20
SCHEMBL1312633	0.76	1/20
SCHEMBL4918470	0.74	1/20
SCHEMBL2010273	0.73	1/20
SCHEMBL3389424	0.73	1/20
SCHEMBL3391015	0.73	1/20
SCHEMBL3393258	0.73	1/20
SCHEMBL3393534	0.73	1/20

Clinical trials — most relevant to CERS2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis	PHASE4	COMPLETED
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.	PHASE4	COMPLETED
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo	PHASE2	COMPLETED
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS)	nan	COMPLETED
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
The Heart-Mind Connection: Evaluating the Association Between Ceramides and Cognitive Decline in Coronary Artery Disease	nan	COMPLETED
Miglustat on Gaucher Disease Type IIIB	nan	UNKNOWN
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function	nan	COMPLETED
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Precision Medicine for Sng/Pain Control	nan	COMPLETED
Rice Ceramide Supplementation and Skin Health	nan	COMPLETED
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention	nan	UNKNOWN
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV	nan	NOT_YET_RECRUITING
Triglyceride-rich LIPoproteins and INflammatory Cytokines After Oral FAT Loading as Potential Early Biomarkers of the Risk of Progression Towards DIABETES and Development of Complications. LIPINFAT Diabetes Study.	nan	RECRUITING
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders	nan	UNKNOWN
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Study of Chediak-Higashi Syndrome	nan	RECRUITING
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)	nan	WITHDRAWN
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis	nan	RECRUITING
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome	nan	COMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CERS2 binder may also engage these)

Protein	Name	Similarity
Q3ZBF8	—	1.000	Q3ZBF8 →
Q924Z4	—	1.000	Q924Z4 →
Q8C172	—	0.994	Q8C172 →
Q6ZMG9	—	0.991	Q6ZMG9 →
Q8N5B7	—	0.990	Q8N5B7 →
Q9HA82	—	0.976	Q9HA82 →
Q5E9R6	—	0.975	Q5E9R6 →
Q6EUN0	—	0.964	Q6EUN0 →
Q6AXM5	—	0.960	Q6AXM5 →
Q8BGS7	—	0.958	Q8BGS7 →
Q3TA38	—	0.958	Q3TA38 →
CEPT1	Choline/ethanolaminephosphotransferase 1	0.958	landscape →
Q9ERM3	—	0.957	Q9ERM3 →
Q5ZKD1	—	0.957	Q5ZKD1 →
A6QPF8	—	0.957	A6QPF8 →
Q9LDF2	—	0.957	Q9LDF2 →
Q9D6K9	—	0.956	Q9D6K9 →
Q63ZG0	—	0.954	Q63ZG0 →
Q7ZYQ3	—	0.953	Q7ZYQ3 →
A0PK00	—	0.953	A0PK00 →
Q28H54	—	0.953	Q28H54 →
A1L2R7	—	0.952	A1L2R7 →
Q1LZE6	—	0.952	Q1LZE6 →
Q5EAX9	—	0.951	Q5EAX9 →
Q1LY80	—	0.951	Q1LY80 →
Q66H21	—	0.950	Q66H21 →
Q6DE21	—	0.950	Q6DE21 →
Q9JI99	—	0.950	Q9JI99 →
Q95K73	—	0.950	Q95K73 →
Q3S8M4	—	0.950	Q3S8M4 →